<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7117553\results\search\disease\results.xml">
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="COVID-19 pandemic has the potential to severely affect those with" exact="rheumatic" post="diseases or who are taking immunosuppressive therapies. Information is"/>
  <result pre="with immunosuppressive therapies. Such therapies are often highly effective for" exact="rheumatic" post="disease treatment but can increase the risk of serious"/>
  <result pre="immunosuppressive therapies. Such therapies are often highly effective for rheumatic" exact="disease" post="treatment but can increase the risk of serious infections1,"/>
  <result pre="face excruciating decisions about which patients should receive access to" exact="limited" post="resources such as mechanical ventilation2. The severe nature of"/>
  <result pre="such as mechanical ventilation2. The severe nature of the SARS-CoV-2" exact="infection" post="also exacerbates resource limitations, asÂ patients often need 15â€&quot;20"/>
  <result pre="present, there is insufficient data as to whether patients with" exact="rheumatic" post="diseases or those using immunosuppressive therapy who contract COVID-19"/>
  <result pre="although researchers are beginning to report COVID-19 in patients with" exact="rheumatic" post="diseases4. Existing literature suggests that there is a substantial"/>
  <result pre="literature suggests that there is a substantial increase in serious" exact="infections" post="in those treated with commonly used anti-rheumatic agents such"/>
  <result pre="inhibitors and glucocorticoids1, and there is a particular risk of" exact="Herpes zoster" post="infection in those patients receiving JAK inhibitors5. However, extrapolation"/>
  <result pre="and glucocorticoids1, and there is a particular risk of Herpes" exact="zoster" post="infection in those patients receiving JAK inhibitors5. However, extrapolation"/>
  <result pre="glucocorticoids1, and there is a particular risk of Herpes zoster" exact="infection" post="in those patients receiving JAK inhibitors5. However, extrapolation of"/>
  <result pre="receiving JAK inhibitors5. However, extrapolation of this data to SARS-CoV-2" exact="infection" post="is problematic given the heterogeneity in specific drug-associated adverse"/>
  <result pre="2002â€&quot;2003 SARS-CoV epidemic and the MERS-CoV that has caused sporadic" exact="infections" post="globally since 2012, comorbid disease or diabetes portended a"/>
  <result pre="MERS-CoV that has caused sporadic infections globally since 2012, comorbid" exact="disease" post="or diabetes portended a worse outcome in some reports6,7,"/>
  <result pre="has caused sporadic infections globally since 2012, comorbid disease or" exact="diabetes" post="portended a worse outcome in some reports6,7, but not"/>
  <result pre="outcome in some reports6,7, but not in others8. However, only" exact="limited" post="data on the disease course of those taking immunosuppressive"/>
  <result pre="but not in others8. However, only limited data on the" exact="disease" post="course of those taking immunosuppressive therapies and who contracted"/>
  <result pre="outbreaks9. Although the adverse effects of drugs used to treat" exact="rheumatic" post="diseases is a major concern, discussions are also taking"/>
  <result pre="taking place about the potential positive effects of some common" exact="rheumatic" post="disease treatments. Antimalarials, JAK inhibitors, IL-1 inhibitors, IL-6 inhibitors,"/>
  <result pre="place about the potential positive effects of some common rheumatic" exact="disease" post="treatments. Antimalarials, JAK inhibitors, IL-1 inhibitors, IL-6 inhibitors, intravenous"/>
  <result pre="the overall goal of efficiently gathering data regarding patients with" exact="rheumatic" post="diseases and immunosuppressive medications during the rapidly evolving pandemic:"/>
  <result pre="collection of case information from physicians who treat those with" exact="rheumatic" post="diseases and is designed to answer two questions: what"/>
  <result pre="two questions: what are the COVID-19 outcomes among patients with" exact="rheumatic" post="diseases, particularly those treated with immunosuppressive therapies; and can"/>
  <result pre="to clinicians on the registry website. Data on patient demographics," exact="rheumatic" post="disease phenotypes, comorbidities, immunosuppressive and other drug therapies and"/>
  <result pre="clinicians on the registry website. Data on patient demographics, rheumatic" exact="disease" post="phenotypes, comorbidities, immunosuppressive and other drug therapies and COVID-19"/>
  <result pre="patient support groups that are administering questionnaires to patients with" exact="rheumatic" post="diseases. Understanding the community burden of COVID-19 in those"/>
  <result pre="diseases. Understanding the community burden of COVID-19 in those with" exact="rheumatic" post="diseases, as well as the patient experience of both"/>
  <result pre="the patient experience of both the pandemic itself and of" exact="infections" post="in general, will be important and complementary to the"/>
  <result pre="payers to analyse administrative data regarding COVID-19 in patients with" exact="rheumatic" post="diseases. This type of data, although not as clinically"/>
  <result pre="knowledge about COVID-19 for the benefit of all patients with" exact="rheumatic" post="diseases. Related links Johns Hopkins Coronavirus Resource Center:https://coronavirus.jhu.edu/map.html The"/>
  <result pre="by the National Institutes of Health (NIH) National Institute of" exact="Arthritis" post="and Musculoskeletal and Skin Diseases (NIAMS) in the form"/>
  <result pre="of Health (NIH) National Institute of Arthritis and Musculoskeletal and" exact="Skin Diseases" post="(NIAMS) in the form of grants (NIH/NIAMS P30 AR070155"/>
  <result pre="Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin" exact="Diseases" post="(NIAMS) in the form of grants (NIH/NIAMS P30 AR070155"/>
  <result pre="AR070155 and NIH/NIAMS K24AR074534), the Alice Betts Endowed Chair in" exact="Arthritis" post="Research and the Russel/Engleman Research Center at the University"/>
  <result pre="J.Y. declares no competing interests. References References 1.FurstDThe risk of" exact="infections" post="with biologic therapies for rheumatoid arthritisSemin. Arthritis Rheum.20103932734619117595 2.RosenbaumLFacing"/>
  <result pre="1.FurstDThe risk of infections with biologic therapies for rheumatoid arthritisSemin." exact="Arthritis" post="Rheum.20103932734619117595 2.RosenbaumLFacing COVID-19 in Italy â€&quot; ethics, logistics, and"/>
  <result pre="J. Med.2020 3.WuZMcGooganJMCharacteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
  <result pre="report of 72 314 cases from the Chinese Center for" exact="Disease" post="Control and PreventionJAMA2020 4.ArentzMet al.Characteristics and outcomes of 21"/>
  <result pre="critically ill patients with COVID-19 in Washington stateJAMA2020 5.WinthropKet al.Herpes" exact="zoster" post="and tofacitinib: clinical outcomes and the risk of concomitant"/>
  <result pre="and risk factors for adverse outcome in patients hospitalised with" exact="acute" post="respiratory disease due to MERS coronavirus or other causesPLoS"/>
  <result pre="risk factors for adverse outcome in patients hospitalised with acute" exact="respiratory" post="disease due to MERS coronavirus or other causesPLoS One201611e016597827812197"/>
  <result pre="factors for adverse outcome in patients hospitalised with acute respiratory" exact="disease" post="due to MERS coronavirus or other causesPLoS One201611e016597827812197 8.LeeNet"/>
  <result pre="or other causesPLoS One201611e016597827812197 8.LeeNet al.A major outbreak of severe" exact="acute" post="respiratory syndrome in Hong KongN. Engl. J. Med.20033481986199412682352 9.GueryBet"/>
  <result pre="other causesPLoS One201611e016597827812197 8.LeeNet al.A major outbreak of severe acute" exact="respiratory" post="syndrome in Hong KongN. Engl. J. Med.20033481986199412682352 9.GueryBet al.Clinical"/>
  <result pre="causesPLoS One201611e016597827812197 8.LeeNet al.A major outbreak of severe acute respiratory" exact="syndrome" post="in Hong KongN. Engl. J. Med.20033481986199412682352 9.GueryBet al.Clinical features"/>
  <result pre="in Hong KongN. Engl. J. Med.20033481986199412682352 9.GueryBet al.Clinical features and" exact="viral" post="diagnosis of two cases of infection with Middle East"/>
  <result pre="9.GueryBet al.Clinical features and viral diagnosis of two cases of" exact="infection" post="with Middle East Respiratory Syndrome coronavirus: a report of"/>
  <result pre="viral diagnosis of two cases of infection with Middle East" exact="Respiratory" post="Syndrome coronavirus: a report of nosocomial transmissionLancet20133812265227223727167 10.US National"/>
  <result pre="diagnosis of two cases of infection with Middle East Respiratory" exact="Syndrome" post="coronavirus: a report of nosocomial transmissionLancet20133812265227223727167 10.US National Library"/>
 </snippets>
</snippetsTree>
